Treatment satisfaction by web survey for chronic spontaneous urticaria in Japa
Not Applicable
- Conditions
- chronic spontaneous urticaria
- Registration Number
- JPRN-UMIN000047616
- Lead Sponsor
- Sanofi K.K.
- Brief Summary
Antihistamines (66.0%) and topical steroids (TCS; 35.0%) were the most common drugs currently used, with 7.8% of patients taking both together. 12.1% of patients received oral steroids (OCS), 9.1% over-the-counter drugs only, and 2.6% anti-IgE antibody. The mean (+/-SD) Global Satisfaction in TSQM-9 was 59.2 +/- 18.4 in the overall population, 59.6 +/- 18.0 for antihistamines, 56.4 +/- 18.5 for TCS, 55.2 +/- 20.9 for OCS, and 54.6 +/- 13.9 for anti-IgE antibody by current drugs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 550
Inclusion Criteria
Not provided
Exclusion Criteria
- Correspond to an inappropriate answer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Summary statistics (e.g., average) of TSQM-9 score - Correlation coefficient between TSQM-9 score and UCT/DLQI/Itch-NRS/Burning sensation NRS/Sleep NRS/SF-8/WPAI:GH score - TSQM-9 score by demographic characteristic - TSQM-9 score by treatment
- Secondary Outcome Measures
Name Time Method - Summary statistics (e.g, average) of UCT/DLQI/SF-8/WPAI:GH scores - Responses to each NRS - Each score by demographic characteristic - Each score by treatment